It all started here at M. D. Anderson with the concept, vector development, preclinical trials and the first phase of testing. This agent has clinical benefit, and because of its novelty and lack of interest by major pharmaceutical companies, the only way to make it available to patients was to start a biotech company. But it has been a long road.